AU781897B2 - Anti-tumor comprising boroproline compounds - Google Patents

Anti-tumor comprising boroproline compounds

Info

Publication number
AU781897B2
AU781897B2 AU52927/00A AU5292700A AU781897B2 AU 781897 B2 AU781897 B2 AU 781897B2 AU 52927/00 A AU52927/00 A AU 52927/00A AU 5292700 A AU5292700 A AU 5292700A AU 781897 B2 AU781897 B2 AU 781897B2
Authority
AU
Australia
Prior art keywords
agent
cancer
administered
carcinoma
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU52927/00A
Other languages
English (en)
Other versions
AU5292700A (en
Inventor
Glenn Miller
Barbara P. Wallner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Point Therapeutics Inc
Original Assignee
Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Point Therapeutics Inc filed Critical Point Therapeutics Inc
Publication of AU5292700A publication Critical patent/AU5292700A/en
Application granted granted Critical
Publication of AU781897B2 publication Critical patent/AU781897B2/en
Priority to AU2005211682A priority Critical patent/AU2005211682A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU52927/00A 1999-05-25 2000-05-25 Anti-tumor comprising boroproline compounds Ceased AU781897B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2005211682A AU2005211682A1 (en) 1999-05-25 2005-09-23 Anti-tumor comprising boroproline compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13586199P 1999-05-25 1999-05-25
US60/135861 1999-05-25
PCT/US2000/014505 WO2000071135A1 (en) 1999-05-25 2000-05-25 Anti-tumor comprising boroproline compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005211682A Division AU2005211682A1 (en) 1999-05-25 2005-09-23 Anti-tumor comprising boroproline compounds

Publications (2)

Publication Number Publication Date
AU5292700A AU5292700A (en) 2000-12-12
AU781897B2 true AU781897B2 (en) 2005-06-23

Family

ID=22470056

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52927/00A Ceased AU781897B2 (en) 1999-05-25 2000-05-25 Anti-tumor comprising boroproline compounds

Country Status (6)

Country Link
EP (1) EP1187619A1 (enExample)
JP (1) JP2003500360A (enExample)
AU (1) AU781897B2 (enExample)
CA (1) CA2373643A1 (enExample)
HK (1) HK1046846A1 (enExample)
WO (1) WO2000071135A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518290A (ja) 1997-09-29 2001-10-16 ポイント セラピューティクス， インコーポレイテッド インビトロでの造血細胞の刺激
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
BR0114604A (pt) 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
WO2003037373A1 (en) * 2001-10-31 2003-05-08 Medical Research Council Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer
JP4771661B2 (ja) * 2001-11-26 2011-09-14 トラスティーズ オブ タフツ カレッジ Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
JP2003267966A (ja) * 2002-03-13 2003-09-25 Pola Chem Ind Inc フラバン誘導体、皮膚線維芽細胞増殖抑制剤および皮膚外用剤
WO2004004661A2 (en) * 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
JP4584245B2 (ja) 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 多発性骨髄腫治療用のアプリジン
WO2004080293A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9284337B2 (en) * 2011-11-22 2016-03-15 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
WO2018056907A1 (en) * 2016-09-21 2018-03-29 Agency For Science, Technology And Research Methods and compositions for inhibiting skin inflammation and determining cancer susceptibility
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
TWI812820B (zh) * 2018-12-10 2023-08-21 美商百歐克斯賽爾治療公司 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法
CN115779148B (zh) * 2021-09-09 2024-02-23 中国科学院福建物质结构研究所 一种牙种植体表面涂层及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5480194A (en) * 1993-02-01 1994-08-04 Rohm And Haas Company POlymerization process for making porous polymeric particles
WO1998025644A1 (en) * 1996-12-10 1998-06-18 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
AU3995899A (en) * 1998-06-05 1999-12-20 Point Therapeutics, Inc. Cyclic boroproline compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02268118A (ja) * 1989-04-07 1990-11-01 Mitsubishi Gas Chem Co Inc 免疫賦活剤
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5767242A (en) * 1994-04-20 1998-06-16 Boehringer Ingelheim Int'l Gmbh Isolated dimeric fibroblast activation protein alpha, and uses thereof
US6100234A (en) * 1997-05-07 2000-08-08 Tufts University Treatment of HIV
CA2339537A1 (en) * 1998-08-21 2000-03-02 Barbara Wallner Regulation of substrate activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5480194A (en) * 1993-02-01 1994-08-04 Rohm And Haas Company POlymerization process for making porous polymeric particles
WO1998025644A1 (en) * 1996-12-10 1998-06-18 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
AU3995899A (en) * 1998-06-05 1999-12-20 Point Therapeutics, Inc. Cyclic boroproline compounds

Also Published As

Publication number Publication date
AU5292700A (en) 2000-12-12
CA2373643A1 (en) 2000-11-30
JP2003500360A (ja) 2003-01-07
EP1187619A1 (en) 2002-03-20
WO2000071135A1 (en) 2000-11-30
HK1046846A1 (zh) 2003-01-30

Similar Documents

Publication Publication Date Title
US7259138B2 (en) Anti-tumor agents
AU5292700A (en) Anti-tumor comprising boroproline compounds
US7601355B2 (en) Compositions and methods for altering immune function
US10174077B2 (en) Method of inhibiting activity of cell surface fibroblast activation protein alpha
EP1578362A2 (en) Boroproline compound combination therapy
WO2006050162A2 (en) Imidazole derivatives
US10155789B2 (en) Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof
WO2018107011A1 (en) P53-targeting vaccines and pd-1 pathway inhibitors and methods of use thereof
US20050267027A1 (en) Use of erythropoietin for treatment of cancer
EP1806138A1 (en) Anti-tumor agents comprising boroproline compounds
US8232318B2 (en) Approaches to treat cancer using HB-EGF inhibitors
AU2005211682A1 (en) Anti-tumor comprising boroproline compounds
WO2007123686A2 (en) Dpp inhibitors and uses thereof
WO2023039399A2 (en) Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
EP4359004A1 (en) Compositions and methods for increasing the efficacy of immunotherapies and vaccines
US20240216465A1 (en) Method for treating refractory brain tumor
WO2007059099A2 (en) Boroproline combination therapy for cancer